scholarly journals Trastuzumab-Resistance and Breast Cancer

10.5772/20936 ◽  
2011 ◽  
Author(s):  
Milos Dokmanovic ◽  
Wen Jin
Keyword(s):  
Breast Cancer ◽  
Trastuzumab Resistance

scholarly journals Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (19) ◽  
pp. 27778-27786 ◽  
Author(s):  
Wentong Li ◽  
Limin Zhai ◽  
Hui Wang ◽  
Chuanliang Liu ◽  
Jinbao Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Trastuzumab Resistance ◽  
Lncrna Gas5

scholarly journals Involvement of microRNA-146a in trastuzumab resistance of HER2+ breast cancer cells

2017 ◽  
Vol 28 ◽  
pp. vii25-vii26
Author(s):  
P. Cabello ◽  
J. Forés ◽  
E. Tormo ◽  
B. Pineda ◽  
A. Adam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Trastuzumab Resistance ◽  
Her2 Breast Cancer

scholarly journals Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulatingPABPC1expression through H3K27 acetylation

2018 ◽  
Vol 22 (10) ◽  
pp. 4935-4947 ◽  
Author(s):  
Huaying Dong ◽  
Wei Wang ◽  
Shaowei Mo ◽  
Qiang Liu ◽  
Xin Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Trastuzumab Resistance ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer

2020 ◽  
Vol 9 (12) ◽  
pp. 3911
Author(s):  
Rita Silva-Oliveira ◽  
Filipa Ferreira Pereira ◽  
Sara Petronilho ◽  
Ana Teresa Martins ◽  
Ana Lameirinhas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Breast Cancer Mortality ◽  
Inverse Association ◽  
Patient Stratification ◽  
Breast Cancer Patients ◽  
Trastuzumab Resistance ◽  
Luminal B ◽  
Her 2

Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contribute to trastuzumab resistance through AKT activation. An association between adenine thymine-rich interactive domain 1A (ARID1A) loss and ANXA1 upregulation was also previously suggested by others. Methods: in this study, we examined tissue samples from 215 HER-2+ breast cancer patients to investigate the value of ARID1A and ANXA1 protein levels in trastuzumab response prediction and patient outcome. Expression of ARID1A and ANXA1 were assessed by immunohistochemistry. Results: contrary to what was expected, no inverse association was found between ARID1A and ANXA1 expression. HER-2+ (non-luminal) tumours displayed higher ANXA1 expression than luminal B-like (HER-2+) tumours. Concerning trastuzumab resistance, ARID1A and ANXA1 proteins did not demonstrate predictive value as biomarkers. Nevertheless, an association was depicted between ANXA1 expression and breast cancer mortality and relapse. Conclusions: overall, our results suggest that ANXA1 may be a useful prognostic marker in HER-2+ patients. Additionally, its ability to discriminate between HER-2+ (non-luminal) and luminal B-like (HER-2+) patients might assist in patient stratification regarding treatment strategy.

Sign in / Sign up

Export Citation Format

Share Document